HK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals

Stock News

11/27

QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1173683741"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173683741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173683741?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173683741","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals","media":"Stock News","content":"<p>QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | QYUNS-B (02509) Surges Over 7% After Repurchasing HKD 18M+ This Month; QX027N Gains Two Clinical Trial Approvals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1173683741","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173683741","pubTimestamp":1764213495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"港股动向|QYUNS-B(02509)本月回购逾1800万港元后急升超7%；QX027N获得两项临床试验批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) rose over 7% in early trading, settling at a 4.97% gain to HKD 21.98 by press time, with a turnover of HKD 8.5648 million. The company announced on November 25 that it repurchased 23,000 shares for HKD 473,000. Data shows continuous share buybacks this month, totaling 901,800 shares acquired at a cumulative cost of HKD 18.2407 million. Additionally, QYUNS-B recently disclosed that its self-developed long-acting bispecific antibody QX027N injection received two implied clinical trial approvals from China's National Medical Products Administration Center for Drug Evaluation. The drug is intended for treating asthma and atopic dermatitis. This milestone marks the company's entry into the clinical stage for its innovative bispecific antibody pipeline in autoimmune and allergic diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}